Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV observational study): analysis of 6-month outcomes
S Gaertner, EM Cordeanu, S Nouri, AM Faller… - International Journal of …, 2017 - Elsevier
Background This study aimed to provide safety and efficacy data of rivaroxaban in routine
patient care in a non-selected symptomatic venous thromboembolism (VTE) population …
patient care in a non-selected symptomatic venous thromboembolism (VTE) population …
Venous thromboembolism therapy with rivaroxaban in daily-care patients: results from the Dresden NOAC registry
L Keller, S Marten, J Hecker, K Sahin, L Tittl… - International Journal of …, 2018 - Elsevier
The effectiveness and safety of acute venous thromboembolism (VTE) treatment with
rivaroxaban, demonstrated in phase-III trials, needs to be confirmed in daily care. To confirm …
rivaroxaban, demonstrated in phase-III trials, needs to be confirmed in daily care. To confirm …
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized …
MH Prins, AWA Lensing, R Bauersachs, B Van Bellen… - Thrombosis journal, 2013 - Springer
Background Standard treatment for venous thromboembolism (VTE) consists of a heparin
combined with vitamin K antagonists. Direct oral anticoagulants have been investigated for …
combined with vitamin K antagonists. Direct oral anticoagulants have been investigated for …
A multicenter prospective observational cohort study to investigate the effectiveness and safety of rivaroxaban in Japanese venous thromboembolism patients (the J' …
Y Okumura, I Fukuda, M Nakamura, N Yamada… - Circulation …, 2020 - jstage.jst.go.jp
Background: There is insufficient real-world data on the current status of Japanese patients
with venous thromboembolism (VTE) or its treatment and prevention with rivaroxaban …
with venous thromboembolism (VTE) or its treatment and prevention with rivaroxaban …
Rivaroxaban for the treatment of venous thromboembolism
N Kucher, D Aujesky, JH Beer… - Thrombosis and …, 2016 - thieme-connect.com
We investigated three-month clinical outcomes in patients with venous thromboembolism
(VTE) treated with rivaroxaban or conventional anticoagulation in routine clinical practice …
(VTE) treated with rivaroxaban or conventional anticoagulation in routine clinical practice …
Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study
Background Deep vein thrombosis (DVT) and pulmonary embolism are collectively known
as venous thromboembolism (VTE), which is a common vascular disease and a major cause …
as venous thromboembolism (VTE), which is a common vascular disease and a major cause …
Rivaroxaban for the treatment of venous thromboembolism. A “real-life” perspective in 103 patients
L Jara-Palomares, R Sanchez-Oro-Gomez… - Thrombosis research, 2014 - Elsevier
Introduction Randomized clinical trials have demonstrated non-inferiority of rivaroxaban
compared with vitamin K antagonists (VKAs) in the treatment of venous thromboembolism …
compared with vitamin K antagonists (VKAs) in the treatment of venous thromboembolism …
Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study
C Sindet-Pedersen, L Staerk… - European Heart …, 2018 - academic.oup.com
Aims To investigate the risk of all-cause mortality, recurrent venous thromboembolism (VTE),
and hospitalized bleeding in patients with VTE treated with either rivaroxaban or apixaban …
and hospitalized bleeding in patients with VTE treated with either rivaroxaban or apixaban …
Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism–the J-EINSTEIN DVT and PE program
N Yamada, A Hirayama, H Maeda, S Sakagami… - Thrombosis journal, 2015 - Springer
Abstract Background The global EINSTEIN DVT and PE studies compared rivaroxaban (15
mg twice daily for 3 weeks followed by 20 mg once daily) with enoxaparin/vitamin K …
mg twice daily for 3 weeks followed by 20 mg once daily) with enoxaparin/vitamin K …
Oral rivaroxaban for symptomatic venous thromboembolism
Einstein Investigators - New England Journal of Medicine, 2010 - Mass Medical Soc
Background Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose
regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without …
regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without …
相关搜索
- venous thromboembolism effectiveness of rivaroxaban
- thromboembolism patients safety of rivaroxaban
- oral rivaroxaban pooled analysis
- venous thromboembolism apixaban in patients
- oral rivaroxaban standard therapy
- venous thromboembolism length of stay
- pooled analysis standard therapy
- venous thromboembolism rivaroxaban and apixaban